Chinese programme 2020: Part I

Language session
Chairs: R. Chen (Guangzhou (Guangdong), China), A. Yorgancioglu (Izmir, Turkey)
Aims: To allow experienced speakers from the ERS leadership and Chinese leaders in respiratory medicine to describe new advances in respiratory medicine; and to present an overview of respiratory diseases, including early diagnosis, public health, sleep, and pulmonary embolism, in Europe and China. This programme will be available in Chinese and English.

Strategy for early diagnosis and intervention in chronic respiratory disease N. Zhong (Guangzhou (Guangdong), China)
Global Alliance Against Chronic Respiratory Diseases (GARD): Beijing call to action to promote lung health C. Wang (Beijing, China)
A randomized, controlled, open-label study to evaluate the efficacy and safety of oral lopinavir-ritonavir in adults hospitalized with COVID-19 virus infection B. CAO (BEIJING, China)
Lessons shared and perspectives in mechanical ventilation for COVID-19 A. Simonds (London, United Kingdom)
ERS advocacy priorities: air pollution, lung cancer screening, new nicotine delivery products and others A. Yorgancioglu (Izmir, Turkey)
Outdoor air pollution and the burden of childhood asthma across Europe D. Rojas-Rueda (fort collins, United States of America)